The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Adjuvant Chemotherapy Improves Survival after Resection of Hepatic Colorectal Metastases: Analysis of Data from Two Continents
Abstract
BACKGROUND: In the US, systemic chemotherapy is often administered after liver resection for hepatic colorectal metastases, even though no clinical trials data directly support this practice. The bias in America for chemotherapeutic treatment has made studies difficult. Until recently, no well accepted staging systems existed to categorize these patients with liver metastases, who have greatly varied prognoses. STUDY DESIGN: All liver resections from an American and from a European tertiary care center performed between 1991 and 1998 were assembled from two prospective databases. Of 792 liver resections, the 518 patients treated with no chemotherapy (379 American, 139 European) were compared with 274 patients treated (240 American, 34 European) with 5-FU-based adjuvant chemotherapy. Patients treated by all other treatment regimens, including regional chemotherapy, were excluded, as were patients who died perioperatively. Patient survival analysis was performed by log-rank, with stratification by the clinical risk score (CRS, a staging system grading risk of recurrence by five clinical parameters: node-positive primary, short disease-free interval, large (> 5 cm) liver tumor, multiple liver tumors, and high carcinoembryonic antigen). RESULTS: Patients subjected to adjuvant chemotherapy had improved survival (p=0.007, log-rank test) even after stratification by clinical risk score (p=0.001, stratified log-rank test). In every clinical risk score category, patients subjected to adjuvant chemotherapy had a higher chance of survival (range 1.3 to 2.0 times). Adjuvant chemotherapy was an independent predictor of outcomes. CONCLUSIONS: This large study, with patients stratified by risk of recurrence, demonstrates that systemic adjuvant chemotherapy, such as a 5-FU-based regimen, prolongs survival after hepatic resection for colorectal metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Portier, G., Elias, D., Bouche, O., Rougier, P., Bosset, J.-F., Saric, J., Belghiti, J., Piedbois, P., Guimbaud, R., Nordlinger, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8353 · Cited by 579
Cited by
Nordlinger, B., Van Cutsem, E., Gruenberger, T., Glimelius, B., Poston, G., Rougier, P., Sobrero, A., & Ychou, M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn735 · Cited by 359
Ychou, M., Hohenberger, W., Thezenas, S., Navarro, M., Maurel, J., Bokemeyer, C., Shacham-Shmueli, E., Rivera, F., Kwok-Keung Choi, C., & Santoro, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp236 · Cited by 271
Metadata
- Authors
- Parks, R., Gonen, M., Kemeny, N., Jarnagin, W., D’Angelica, M., DeMatteo, R., Garden, J. O., Blumgart, L. H., & Fong, Y.
- Venue
- Journal of the American College of Surgeons
- Published
- 2007-05
- Volume
- 204
- Issue
- 5
- Pages
- 753-761
- ISSN
- 1072-7515 (ISSN-L)
- OpenAlex
- W1963830680
- Cited by
- 161
- References
- 4
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.